- Home
- PYPD vs IGC Comparison
PYPD vs IGC Comparison
Compare PYPD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- IGC
- Stock Information
- Founded
- PYPD 2008
- IGC 2005
- Country
- PYPD Israel
- IGC United States
- Employees
- PYPD N/A
- IGC N/A
- Industry
- PYPD Medical/Dental Instruments
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- IGC Health Care
- Exchange
- PYPD Nasdaq
- IGC Nasdaq
- Market Cap
- PYPD 30.1M
- IGC 29.4M
- IPO Year
- PYPD 2020
- IGC N/A
- Fundamental
- Price
- PYPD $2.99
- IGC $0.30
- Analyst Decision
- PYPD Strong Buy
- IGC Strong Buy
- Analyst Count
- PYPD 2
- IGC 2
- Target Price
- PYPD $10.50
- IGC $3.75
- AVG Volume (30 Days)
- PYPD 18.1K
- IGC 399.9K
- Earning Date
- PYPD 02-12-2025
- IGC 03-04-2025
- Dividend Yield
- PYPD N/A
- IGC N/A
- EPS Growth
- PYPD N/A
- IGC N/A
- EPS
- PYPD N/A
- IGC N/A
- Revenue
- PYPD N/A
- IGC $1,236,000.00
- Revenue This Year
- PYPD N/A
- IGC N/A
- Revenue Next Year
- PYPD N/A
- IGC $13.38
- P/E Ratio
- PYPD N/A
- IGC N/A
- Revenue Growth
- PYPD N/A
- IGC 1.64
- 52 Week Low
- PYPD $2.37
- IGC $0.27
- 52 Week High
- PYPD $6.58
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- PYPD 49.42
- IGC 38.51
- Support Level
- PYPD $2.89
- IGC $0.29
- Resistance Level
- PYPD $3.27
- IGC $0.33
- Average True Range (ATR)
- PYPD 0.28
- IGC 0.01
- MACD
- PYPD 0.00
- IGC -0.00
- Stochastic Oscillator
- PYPD 45.89
- IGC 15.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.